<DOC>
	<DOCNO>NCT01193959</DOCNO>
	<brief_summary>Present study aim investigate potential molecular predictor sensitivity resistance single-agent pemetrexed â‰¥ second line set large cohort advance non-small cell lung cancer ( NSCLC ) patient . The following biomarkers investigate either immunohistochemistry , fluorescence situ hybridization genotyping : thymidylate synthase ( TS ) , dihydrofolate reductase ( DHFR ) , glycinamide ribonucleotide formyl transferase ( GARFT ) , aminoimidazole carboxamide ribonucleotide formyltransferase ( ATIC/AICARFT ) , epidermal growth factor receptor ( EGFR ) , Kirsten rat sarcoma 2 viral oncogene homolog ( KRAS ) , v-myc myelocytomatosis viral oncogene homolog ( MYC ) phosphoinositide-3-kinase , catalytic , alpha polypeptide ( PIK3CA ) .</brief_summary>
	<brief_title>Pemetrexed Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically confirm diagnosis advance nonsmall cell lung cancer Tumor tissue available institution Patients treat single agent pemetrexed metastatic disease Availability full clinical data Cytological diagnosis advance Nonsmall cell lung cancer Lack tumor tissue institution Lack full clinical data</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>